Botox sales boost Allergan's bottom line
This article was originally published in Scrip
Executive Summary
Forget what the scholarly economic experts and pundits have said about the world economic recession. While the impact of the financial meltdown could be measured by the number of new wrinkles on the faces of Wall Street, the signs of economic recovery could be gauged by new spending for Botox (onabotulinumtoxinA), with Allergan reporting in its fourth-quarter earnings that sales of the drug jumped 11% from $347.7 million in 2009 to $386.2 million in 2010, with cosmetic uses accounting for about half of those sales.